NCT00336778View on ClinicalTrials.gov

Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
HIV Infections
Interventions
DRUG

3TC, TDF, NLV

3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)

Trial Locations (2)

21201

University of Maryland Baltimore, Institute of Human Virology, Baltimore

21210

University of Maryland, Institute of Human Virology, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT00336778 - Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression | Biotech Hunter | Biotech Hunter